The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories ยท page 8 of 23

Stories

  1. Takeda posts results of Phase 3 TAK-279 study in psoriasis

    The study enrolled 18 participants and completed primary data collection on October 17, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.

  2. Alexion posts results of Phase 3 ravulizumab trial in HSCT-TMA

    The study enrolled 148 participants and completed primary data collection on September 19, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.

  3. Novo Nordisk posts results of Phase 3 KBP-5074 trial in uncontrolled hypertension and CKD

    The study enrolled 666 participants and began on November 5, 2021, with primary completion on January 30, 2024. The trial was terminated and the results were first posted on ClinicalTrials.gov on November 4, 2026.

  4. Cognixion enrolls participants in NIH-funded BCI study for ALS

    Cognixion Corporation announced it is now enrolling 30 adults with ALS in the CHOICE study, a 12-week trial comparing its investigational brain-computer interface with eye-tracking devices. The study is supported by the National Institute on Deafness and Other Communication Disorders and is registered on ClinicalTrials.gov as NCT07871071.

  5. Minghui and ASKA enter exclusive license for MHB018A in Japan

    Minghui Pharmaceutical and ASKA Pharmaceutical announced an exclusive license agreement for the development and commercialization of MHB018A in Japan, with ASKA receiving rights to seek regulatory approval and commercialize the antibody. The agreement includes an upfront payment of USD 110 million and potential milestone payments of up to USD 330 million, plus tiered royalties up to mid-30 % on net sales in Japan.

  6. Median overall survival was 11.3 months on epcoritamab and 10.3 months on chemotherapy in DLBCL

    In the 483-person Phase 3 trial, median overall survival was 11.3 months on epcoritamab and 10.3 months on investigator's choice chemotherapy, with a hazard ratio of 0.96. Genmab's registry results now give sites and sponsors the randomized comparison in relapsed or refractory DLBCL.

  7. Thryv Therapeutics announces $30 million financing to launch ASPIRE-HF study

    The company secured $30 million Series B financing led by InClin, Inc. to fund the Phase 2a ASPIRE-HF study in heart failure with reduced ejection fraction and QTc prolongation, which opens for enrollment in early 2027. Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, has completed enrollment of its first efficacy cohort, with data expected in early 2027.

  8. Xtalks hosts webinar on smarter site selection for early-phase trials

    The webinar, scheduled for Tuesday, November 17, 2026 at 11am EST, will explore how early-phase biotech teams can improve enrollment predictability by integrating recruitment into study design and site selection. Speakers include Chris Morris of PPD, Irina Strachkova of Patient First Digital Solutions, and Dr. Lukasz Wiech of Trialmed.

  9. Hutchmed registers Phase III trial of HMPL-306 in postoperative residual or recurrent grade 2 glioma

    The study plans to enroll 210 participants and plans to begin in November 2026, with primary completion projected for March 2032. It is a randomized, double-blind, placebo-controlled multicenter Phase III trial evaluating HMPL-306 tablet safety and efficacy.

  10. Phase 3 results posted, week of November 2, 2026: 11 industry trials

    Industry sponsors posted results for 11 Phase 3 trials on ClinicalTrials.gov in the week of November 2 to 8, 2026. Together the trials enrolled 6,267 participants; the largest, Novartis Pharmaceuticals' KALUMA trial, enrolled 1,720.

  11. Jiangsu HengRui Medicine registers Phase 3 trial of SHR-3167 vs insulin degludec in type 2 diabetes

    The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll an estimated 680 participants and plans to start in November 2026. It is a multicenter, randomized, open-label Phase III trial comparing once-weekly SHR-3167 with once-daily insulin degludec over up to 33 weeks.

  12. Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL

    Results for the EPCORE DLBCL-1 study were first posted on ClinicalTrials.gov on November 3, 2026. The randomized, open-label Phase 3 trial enrolled 483 participants and compared subcutaneous epcoritamab with investigator's choice chemotherapy (R-GemOx or BR) in relapsed/refractory diffuse large B-cell lymphoma.